imatinib mesylate has been researched along with Carcinoma, Small Cell in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (96.77) | 29.6817 |
| 2010's | 1 (3.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budd, GT; Chao, J; Chow, WA; Chu, P; Frankel, P; Garcia, D; Junqueira, M; Loera, S; Sato, J; Somlo, G | 1 |
| Smit, EF | 1 |
| Abrams, TJ; Cherrington, JM; Lee, LB; Murray, LJ; Pryer, NK | 1 |
| Chevalier, TL; Johnson, BE; Soria, JC | 1 |
| Heinrich, MC | 1 |
| Dimitrijevic, S; Dunlop, D; Fischer, B; Fischer, T; Fletcher, C; Hornick, J; Johnson, BE; Kowalski, MO; Le Chevalier, T; Rischin, D; Salgia, R; Sayles, D; Silberman, S | 1 |
| Fossella, FV; Murray, N; Salgia, R | 1 |
| Buchdunger, E; García-Echeverría, C; Hofmann, F; Krystal, GW; Litz, J; Warshamana-Greene, GS | 1 |
| Gillenwater, HH; Wolf, T | 1 |
| Johnson, BE | 1 |
| Egorin, MJ; Ilaria, RL; Minna, JD; Randle, DE; Wolff, NC | 1 |
| Chua, YJ; Steer, C; Yip, D | 1 |
| de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C | 1 |
| Cheng, L; Eble, JN; Jones, TD; Koch, MO; Lin, H; Lopez-Beltran, A; MacLennan, GT; Nigro, K; Pan, CX; Papavero, V; Tretiakova, M; Yang, XJ | 1 |
| Bharti, A; Broderick, RJ; Khan, E; Kijima, T; Maulik, G; Salgia, R | 1 |
| Gambacorti-Passerini, C; Piazza, R; Pilotti, S; Pogliani, E; Tornaghi, L | 1 |
| Miyazawa, K; Ohyashiki, K; Yokoyama, T; Yoshida, T | 1 |
| Azzoli, CG; Crapanzano, JP; Dunne, M; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Rizvi, N; Tyson, L | 1 |
| Adjei, AA; Aubry, MC; Dy, GK; Jett, JR; Langdon, RM; Mandrekar, SJ; Miller, AA; Morton, RF; Schild, SE | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS; Turen, S | 1 |
| Dennis, PA; Gills, JJ; Sayyah, J; Tsurutani, J; West, KA | 1 |
| Glisson, BS; Johnson, FM; Krug, LM; Patel, J; Peeples, B; Prieto, VG; Shoaf, S; Tamboli, P; Tran, HT | 1 |
| Krystal, GW; Litz, J | 1 |
| Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Asaumi, N; Niiya, K; Niiya, M; Shibakura, M; Tanimoto, M; Yoshida, C | 1 |
| Heath, J; Kanwar, VS; Krasner, CN; Pearce, JM | 1 |
| Griffin, JD; Healy, ME; Johnson, BE; Lin, J; Maulik, G; Salgia, R; Sattler, M; Stiles, CD; Verma, S; Wang, WL | 1 |
| Buchdunger, E; Honsawek, S; Krystal, GW; Litz, J | 1 |
| Hochhaus, A | 1 |
| Nokihara, H; Ohe, Y | 1 |
6 review(s) available for imatinib mesylate and Carcinoma, Small Cell
| Article | Year |
|---|---|
Targeted molecules in small cell lung cancer.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Humans; Imatinib Mesylate; Immunoconjugates; Lung Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
Treatment options for small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiotherapy, Adjuvant; Risk Factors; Sex Distribution; Smoking; Survival Rate; Treatment Outcome; United States | 2004 |
Recent advances in management of small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cancer Vaccines; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Genetic Therapy; Growth Substances; Humans; Imatinib Mesylate; Interferons; Lung Neoplasms; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Smoking; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2004 |
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous | 2005 |
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors | 2002 |
[Recent progress in the treatment of ED small cell lung cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Piperazines; Pyrimidines; Vincristine | 2002 |
7 trial(s) available for imatinib mesylate and Carcinoma, Small Cell
| Article | Year |
|---|---|
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neuroectodermal Tumors, Primitive; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; Survival Rate; Treatment Outcome | 2010 |
Imatinib in small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2003 |
Phase II study of imatinib in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2003 |
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Edema; Fatigue; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Failure | 2005 |
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Salvage Therapy; Survival Rate | 2005 |
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial | 2008 |
18 other study(ies) available for imatinib mesylate and Carcinoma, Small Cell
| Article | Year |
|---|---|
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cell Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
Is KIT an important therapeutic target in small cell lung cancer?
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2003 |
The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Growth Substances; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Lung Neoplasms; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, IGF Type 1; Serum; Signal Transduction; Stem Cell Factor | 2004 |
Imatinib for small cell lung cancer, aiming for a target in vivo.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Cell Line, Tumor; Clinical Trials as Topic; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines | 2004 |
Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; NIH 3T3 Cells; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor; Time Factors; Tyrosine | 2004 |
c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Carcinoma, Small Cell; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms | 2005 |
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Topoisomerase I Inhibitors | 2004 |
Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Bronchoscopy; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Lung Neoplasms; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Factor; Vitamin K 2 | 2005 |
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Cell Adhesion; Cell Survival; Chromones; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; Laminin; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Electrophoretic Mobility Shift Assay; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Signal Transduction; Stem Cell Factor; Transcription, Genetic; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Topics: Benzamides; Carcinoma, Small Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interleukin-8; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Transcriptional Activation; Urokinase-Type Plasminogen Activator | 2007 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small Cell; Celecoxib; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Lung Neoplasms; Megakaryocytes; Mice; Microscopy, Video; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2000 |
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Topics: Antineoplastic Agents; Benzamides; Carboplatin; Carcinoma, Small Cell; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Imatinib Mesylate; Lung Neoplasms; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stem Cell Factor; Tumor Cells, Cultured | 2000 |